Co-Sourcing Improves Pharmaceutical Laboratory Productivity
Capitol Hill Critics Second-Guess Agencies Using...
Loss of Lives in Clinical Trials...
Reader Contributions Are Encouraged So We...
For full access to this article login to GEN Select now.
An increasing flow of cancer therapeutics and diagnostics is allowing clinicians to more accurately target therapies to treat a broad range of cancer subtypes. [Alexander Raths-Fotolia.com]
As recently as ten years ago, just after completion of the Human Genome Project, the concept of a personalized approach to cancer treatment was ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.Do you agree that ecstasy should be studied for its potential therapeutic benefits?
Be sure to add [email protected]
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2016 Genetic Engineering & Biotechnology News All Rights Reserved